Kim Kelderman

At Bio-Techne, we’re passionate about bringing customers the tools they need to overcome challenges and drive breakthroughs in neurodegenerative disease research.One barrier for researchers to date...

Inspiring conversations with investors and industry leaders at this week’s hashtag#JPM2026 on how Bio-Techne continues to drive growth through our durable and differentiated product portfolio, loya...

Looking forward to the exciting milestones ahead for Bio-Techne in 2026 – including celebrating 50 years of innovation and impact.

What a year! 2025 brought its share of challenges, but the resilience and creativity of the Bio-Techne team turned those challenges into opportunities. Together, we continued to innovate, launch ne...

Organoids are mini organs - with huge potential! At last week’s executive leadership team meeting in Minneapolis, we heard from Hannah Maple, Senior Director, Organoids Portfolio, about why Bio-Tec...

To mark the launch of the Bio-Techne 2025 Sustainability Report, I connected with Erin Woodward, Director of Sustainability, to see examples of our sustainability commitments in action. I’m proud ...

Neurodegenerative disease research is deeply personal to me, and I’m proud of the impact Bio-Techne is making in the field. Every step forward brings us closer to earlier detection and better outco...

Delighted to join the Board of Directors at CONMED Corporation, a global medical technology company committed to supporting healthcare partners and patients through the development, manufacturing, ...

Inspiring discussions on healthcare megatrends and the future of our industry at the Wells Fargo Healthcare Conference this week. Grateful for the opportunity to connect with industry leaders, shar...

Last week we came together as one Bio-Techne team to celebrate our achievements in fiscal year 2025 and look ahead to the next twelve months of catalyzing advances in science and medicine. What sto...